GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (FRA:3XV) » Definitions » ROIC %
中文

Xvivo Perfusion AB (FRA:3XV) ROIC %

: -3.95% (As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Xvivo Perfusion AB's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -3.95%.

As of today (2024-04-23), Xvivo Perfusion AB's WACC % is 4.32%. Xvivo Perfusion AB's ROIC % is 0.33% (calculated using TTM income statement data). Xvivo Perfusion AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Xvivo Perfusion AB ROIC % Historical Data

The historical data trend for Xvivo Perfusion AB's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 -5.49 -2.40 0.28 0.34

Xvivo Perfusion AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 2.54 0.57 3.08 -3.95

Competitive Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB ROIC % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's ROIC % distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's ROIC % falls into.



Xvivo Perfusion AB ROIC % Calculation

Xvivo Perfusion AB's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=0.482 * ( 1 - 2.85% )/( (131.629 + 143.205)/ 2 )
=0.468263/137.417
=0.34 %

where

Xvivo Perfusion AB's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-5.332 * ( 1 - -4.44% )/( (138.87 + 143.205)/ 2 )
=-5.5687408/141.0375
=-3.95 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (FRA:3XV) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Xvivo Perfusion AB's WACC % is 4.32%. Xvivo Perfusion AB's ROIC % is 0.33% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Xvivo Perfusion AB ROIC % Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (FRA:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (FRA:3XV) Headlines

No Headlines